-
Je něco špatně v tomto záznamu ?
Study of aberrant modifications in peptides as a test bench to investigate the immunological response to non-enzymatic glycation
F. Nuti, A. Gallo, F. Real-Fernandez, C. Rentier, G. Rossi, F. Piarulli, P. Traldi, S. Carganico, P. Rovero, A. Lapolla, A. M. Papini
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
ProQuest Central
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
- MeSH
- diabetes mellitus 1. typu metabolismus MeSH
- glykosylace MeSH
- glyoxal metabolismus MeSH
- imidazoly metabolismus MeSH
- imunoanalýza MeSH
- ketosy metabolismus MeSH
- lidé MeSH
- lysin chemie metabolismus MeSH
- peptidy chemie metabolismus MeSH
- posttranslační úpravy proteinů MeSH
- produkty pokročilé glykace metabolismus MeSH
- pyruvaldehyd metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
A side effect of diabetes is formation of glycated proteins and, from them, production of advanced early glycation end products that could determine aberrant immune responses at the systemic level. We investigated a relevant aberrant post-translational modification (PTM) in diabetes based on synthetic peptides modified on the lysine side chain residues with 1-deoxyfructopyranosyl moiety as a possible modification related to glycation. The PTM peptides were used as molecular probes for detection of possible specific autoantibodies developed by diabetic patients. The PDC-E2(167-186) sequence from the pyruvate dehydrogenase complex was selected and tested as a candidate peptide for antibody detection. The structure-based designed type I' β-turn CSF114 peptide was also used as a synthetic scaffold. Twenty-seven consecutive type 1 diabetic patients and 29 healthy controls were recruited for the study. In principle, the 'chemical reverse approach', based on the use of patient sera to screen the synthetic modified peptides, leads to the identification of specific probes able to characterize highly specific autoantibodies as disease biomarkers of autoimmune disorders. Quite surprisingly, both peptides modified with the (1-deoxyfructosyl)-lysine did not lead to significant results. Both IgG and IgM differences between the two populations were not significant. These data can be rationalized considering that i) IgGs in diabetic subjects exhibit a high degree of glycation, leading to decreased functionality; ii) IgGs in diabetic subjects exhibit a privileged response vs proteins containing advanced glycation products (e.g., methylglyoxal, glyoxal, glucosone, hydroimidazolone, dihydroxyimidazolidine) and only a minor one with respect to (1-deoxyfructosyl)-lysine.
Diabetology and Dietetics Department of Medicine University of Padova Padova Italy
Istituto di Ricerca Pediatrica Città della Speranza Padova Italy
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20010291
- 003
- CZ-PrNML
- 005
- 20200721125336.0
- 007
- ta
- 008
- 200707s2019 xr ad f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)31903893
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Nuti, F. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
- 245 10
- $a Study of aberrant modifications in peptides as a test bench to investigate the immunological response to non-enzymatic glycation / $c F. Nuti, A. Gallo, F. Real-Fernandez, C. Rentier, G. Rossi, F. Piarulli, P. Traldi, S. Carganico, P. Rovero, A. Lapolla, A. M. Papini
- 504 __
- $a Literatura
- 520 9_
- $a A side effect of diabetes is formation of glycated proteins and, from them, production of advanced early glycation end products that could determine aberrant immune responses at the systemic level. We investigated a relevant aberrant post-translational modification (PTM) in diabetes based on synthetic peptides modified on the lysine side chain residues with 1-deoxyfructopyranosyl moiety as a possible modification related to glycation. The PTM peptides were used as molecular probes for detection of possible specific autoantibodies developed by diabetic patients. The PDC-E2(167-186) sequence from the pyruvate dehydrogenase complex was selected and tested as a candidate peptide for antibody detection. The structure-based designed type I' β-turn CSF114 peptide was also used as a synthetic scaffold. Twenty-seven consecutive type 1 diabetic patients and 29 healthy controls were recruited for the study. In principle, the 'chemical reverse approach', based on the use of patient sera to screen the synthetic modified peptides, leads to the identification of specific probes able to characterize highly specific autoantibodies as disease biomarkers of autoimmune disorders. Quite surprisingly, both peptides modified with the (1-deoxyfructosyl)-lysine did not lead to significant results. Both IgG and IgM differences between the two populations were not significant. These data can be rationalized considering that i) IgGs in diabetic subjects exhibit a high degree of glycation, leading to decreased functionality; ii) IgGs in diabetic subjects exhibit a privileged response vs proteins containing advanced glycation products (e.g., methylglyoxal, glyoxal, glucosone, hydroimidazolone, dihydroxyimidazolidine) and only a minor one with respect to (1-deoxyfructosyl)-lysine.
- 650 _2
- $a diabetes mellitus 1. typu $x metabolismus $7 D003922
- 650 _2
- $a produkty pokročilé glykace $x metabolismus $7 D017127
- 650 _2
- $a glykosylace $7 D006031
- 650 _2
- $a glyoxal $x metabolismus $7 D006037
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imidazoly $x metabolismus $7 D007093
- 650 _2
- $a imunoanalýza $7 D007118
- 650 _2
- $a ketosy $x metabolismus $7 D007661
- 650 _2
- $a lysin $x chemie $x metabolismus $7 D008239
- 650 _2
- $a peptidy $x chemie $x metabolismus $7 D010455
- 650 _2
- $a posttranslační úpravy proteinů $7 D011499
- 650 _2
- $a pyruvaldehyd $x metabolismus $7 D011765
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gallo, A. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
- 700 1_
- $a Real-Fernandez, F. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
- 700 1_
- $a Rentier, C. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; PeptLab@UCP Platform and Laboratory of Chemical Biology EA4505, University Paris-Seine, Cergy-Pontoise CEDEX, France
- 700 1_
- $a Rossi, G. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy; Pharma Quality Europe PQE SrL, Località Prulli, Firenze, Italy
- 700 1_
- $a Piarulli, F. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
- 700 1_
- $a Traldi, P. $u Istituto di Ricerca Pediatrica, Città della Speranza, Padova, Italy
- 700 1_
- $a Carganico, S. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy. Pharma Quality Europe PQE SrL, Località Prulli, Firenze, Italy
- 700 1_
- $a Rovero, P. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy
- 700 1_
- $a Lapolla, A. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
- 700 1_
- $a Papini, A. M. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; PeptLab@UCP Platform and Laboratory of Chemical Biology EA4505, University Paris-Seine, Cergy-Pontoise CEDEX, France
- 773 0_
- $w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 4 (2019), s. 195-202
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31903893 $y Pubmed
- 856 41
- $u https://fb.cuni.cz/file/5905/fb2019a0020.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 970 $c 89 $y p $z 0
- 990 __
- $a 20200707 $b ABA008
- 991 __
- $a 20200710110840 $b ABA008
- 999 __
- $a ok $b bmc $g 1546286 $s 1100383
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 65 $c 4 $d 195-202 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
- LZP __
- $b NLK118 $a Pubmed-20200707